Structure via PubChem · Public domain (PubChem)
tucatinib
Sign in to saveAlso known as ONT-380, ARRY-380
Tucatinib, sold under the brand name Tukysa, is an anticancer medication used for the treatment of HER2-positive breast cancer. It is a small molecule inhibitor of HER2. It was developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly Oncothyreon, subsequently part of Seattle Genetics).
Chemical data
- Formula
- C26H24N8O2
- Molecular weight
- 480.5 g/mol
- IUPAC name
- 6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine
- SMILES
- CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5
- InChIKey
- SDEAXTCZPQIFQM-UHFFFAOYSA-N
- XLogP
- 4
- Polar surface area
- 111 Ų
- H-bond donors
- 2
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2020
- Admin. routes
- oral
- Indications
- liver disease, angiosarcoma, HER2 Positive Breast Carcinoma, breast cancer
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 480.202
- Has use
- medication
Show 5 more facts
- subject has role
- protein kinase inhibitors
- medical condition treated
- breast cancer
- physically interacts with
- Erb-b2 receptor tyrosine kinase 2
- canonical SMILES
- CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5
- chemical formula
- C₂₆H₂₄N₈O₂
via Wikidata · CC0
~6 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Clinical trials
- History
- Society and culture
- Economics
- Legal status
- Names
- References
- External links
Tucatinib, sold under the brand name Tukysa, is an anticancer medication used for the treatment of HER2-positive breast cancer. It is a small molecule inhibitor of HER2. It was developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly Oncothyreon, subsequently part of Seattle Genetics).
Common side effects include diarrhea, palmar-plantar erythrodysesthesia (burning or tingling discomfort in the hands and feet), nausea, fatigue, hepatotoxicity (liver damage), vomiting, stomatitis (inflammation of the mouth and lips), decreased appetite, abdominal pain, headache, anemia and rash. Tucatinib may cause harm to a developing fetus or baby.
Excerpted from Wikipedia’s “tucatinib” article, available under the CC BY-SA 4.0 licence.